Trials / Recruiting
RecruitingNCT07222332
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 1 Year – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2026-02-05
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
- First posted
- 2025-10-29
- Last updated
- 2026-04-17
Locations
132 sites across 19 countries: United States, Australia, Belgium, Brazil, Canada, Czechia, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07222332. Inclusion in this directory is not an endorsement.